However, treatment with Ang 1-7 decreases visceral adipose tissue mass and adipose leptin, suggesting that the ACE2/Ang 1-7 pathway could be a potential therapeutic target for obesity and T2DM [33,87,88]. Here, ACE2 is linked to obesity disorder.